Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2) is a PHASE3 clinical asset sponsored by Eli Lilly and Company in Type 2 Diabetes, Overweight, Obesity. SEO and diligence focus: Tirzepatide, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.